Mechanism

treatment

comparator

All cause death

Coronary event

Adverse events

Cardiovascular death

Fatal MI

Major bleeding

Non fatal stroke

Non fatal MI

Non vascular death

stroke (fatal and non fatal)

cardiovascular events

Aspirin

coronary artery disease, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.90 [0.80 1.01]	p=1.00	0	12636	8	CDPA, Cardiff I, Cardiff II, Vogel, AMIS, GAMIS, PARIS, JAMIS,
Coronary event	no data
Adverse events	no data
Cardiovascular death	0.73 [0.60 0.90]	p=0.04	0	6600	5	CDPA, Vogel, PARIS, JAMIS, SAPAT,
Fatal MI	0.42 [0.22 0.80]	p=0.04	0	1966	2	Vogel, GAMIS,
Major bleeding	no data
Major bleeding	no data
Non fatal stroke	0.79 [0.44 1.41]	p=1.00	0	2035	1	SAPAT,
Non fatal MI	0.70 [0.60 0.82]	p=0.04	0	11750	7	CDPA, Vogel, AMIS, GAMIS, PARIS, JAMIS, SAPAT,
Non vascular death	1.66 [0.78 3.54]	p=1.00	0	2035	1	SAPAT,
stroke (fatal and non fatal)	no data
cardiovascular events	0.71 [0.55 0.92]	p=0.04	0	2035	1	SAPAT,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CDPA, 1976	Aspirin (324 mg) 3x/d	Placebo	MI survivors
Cardiff I, 1974	Aspirin (300 mg) 1x/d	Placebo	MI survivors
Cardiff II, 1979	Aspirin (300 mg) 3x/d for one year	Placebo	patients with myocardial infarction
Vogel, 1979	Aspirin (1.5 g daily) on an average period of 22 months	Placebo
AMIS, 1980	Aspirin (500 mg) 2x/d for at least 3 years	Placebo	men and women who had had a documented myocardial infarction
GAMIS, 1980	Aspirin (500 mg) 3x/d for 2 years	Placebo	patients who had survived a myocardial infarction for 30-42 days
PARIS, 1980	Aspirin (324 mg) 3x/d	Placebo	patients who had recovered from myocardial infarction
JAMIS, 1999	Aspirin (81 mg) 1x/d	No antiplatelets	patients with AMI within 1 month from the onset of symptoms
SAPAT, 1992	aspirin 75 mg daily	placebo	patients with stable chronic angina pectoris

Clopidogrel

coronary artery disease, in all type of patients

vs aspirin

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.98 [0.87 1.10]	p=1.00	0	19185	1	CAPRIE,
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Fatal MI	0.71 [0.50 1.00]	p=1.00	0	19185	1	CAPRIE,
Major bleeding	no data
Major bleeding	no data
Non fatal stroke	no data
Non fatal MI	0.85 [0.71 1.00]	p=1.00	0	19185	1	CAPRIE,
Non vascular death	no data
stroke (fatal and non fatal)	no data
cardiovascular events	0.90 [0.60 1.35]	p=1.00	0	1001	1	ASCET,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CAPRIE, 1996	Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years	Aspirin (325 mg) 1x/d	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease
ASCET,	clopidogrel 75 mg once daily for two years	Aspirin 160 mg once daily for two years	patients with documented coronary heart disease and treated with aspirin

Dipyridamol

coronary artery disease, in all type of patients

vs control

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	2.21 [0.30 16.24]	p=1.00	0	143	3	Atlanta (Sbar), Becker, Wirecki,
Fatal MI	no data
Major bleeding	no data
Major bleeding	no data
Non fatal stroke	1.57 [0.19 13.12]	p=1.00	0	143	3	Atlanta (Sbar), Becker, Wirecki,
Non fatal MI	0.80 [0.20 3.18]	p=1.00	0	143	3	Atlanta (Sbar), Becker, Wirecki,
Non vascular death	0.98 [0.10 9.64]	p=1.00	0	143	3	Atlanta (Sbar), Becker, Wirecki,
stroke (fatal and non fatal)	no data
cardiovascular events	1.37 [0.40 4.74]	p=1.00	0	143	3	Atlanta (Sbar), Becker, Wirecki,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
Atlanta (Sbar), 1967	dipyridamole 150mg daily	placebo	patients with angina pectoris
Becker, 1967	dipyridamole 225mg daily	placebo
Wirecki, 1967	dipyridamole 150mg daily	placebo	patients with angina pectoris

Dipyridamol

coronary artery disease, in all type of patients

vs placebo

by 31%

by 39%

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.92 [0.74 1.15]	p=1.00	0	4344	2	PARIS, PARIS-II,
Coronary event	no data
Adverse events	no data
Cardiovascular death	0.88 [0.70 1.11]	p=1.00	0	4344	2	PARIS, PARIS-II,
Fatal MI	no data
Major bleeding	no data
Major bleeding	no data
Non fatal stroke	no data
Non fatal MI	0.69 [0.54 0.88]	p=0.04	0	4344	2	PARIS, PARIS-II,
Non vascular death	no data
stroke (fatal and non fatal)	0.61 [0.38 0.99]	p=0.04	0	4344	2	PARIS, PARIS-II,
cardiovascular events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
PARIS, 1980	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d	Placebo	patients who had recovered from myocardial infarction
PARIS-II, 1986	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d	Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously
Igloe, 1970	Dipyridamole 200mg daily	placebo	patients with angina pectoris
Zion, 1961	Dipyridamole 37.5mg	placebo	patients with angina pectoris
Kinsella, 1962	dipyridamole 37.5 mg and 100mg daily	placebo
Leiberman, 1964	dipyridamole 100mg daily	placebo
Dewar, 1961	Dipyridamole 100mg daily	placebo	patients with angina pectoris
Neumann, 1964	dipyridamole 150mg daily	placebo	elderly with precordial pain
Foulds, 1960	Dipyridamole 200mg daily	placebo	patients with angina pectoris

Dipyridamol

coronary artery disease, in all type of patients

vs aspirin

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.02 [0.75 1.40]	p=1.00	0	1620	1	PARIS,
Coronary event	1.05 [0.80 1.36]	p=1.00	0	1620	1	PARIS,
Adverse events	no data
Cardiovascular death	0.99 [0.70 1.38]	p=1.00	0	1620	1	PARIS,
Fatal MI	no data
Major bleeding	no data
Major bleeding	no data
Non fatal stroke	no data
Non fatal MI	1.14 [0.79 1.66]	p=1.00	0	1620	1	PARIS,
Non vascular death	no data
stroke (fatal and non fatal)	1.11 [0.45 2.75]	p=1.00	0	1620	1	PARIS,
cardiovascular events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
PARIS, 1980	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d	Aspirin (324 mg) 3x/d	patuents who had recovered from myocardial infarction

Ticlopidine

coronary artery disease, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	0.81 [0.02 43.03]	p=1.00	0	38	1	Berglund,
Fatal MI	no data
Major bleeding	no data
Major bleeding	no data
Non fatal stroke	0.81 [0.02 43.03]	p=1.00	0	38	1	Berglund,
Non fatal MI	0.81 [0.02 43.03]	p=1.00	0	38	1	Berglund,
Non vascular death	0.81 [0.02 43.03]	p=1.00	0	38	1	Berglund,
stroke (fatal and non fatal)	no data
cardiovascular events	0.81 [0.02 43.03]	p=1.00	0	38	1	Berglund,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
Berglund, 1985	ticlopidine 500 mg daily	placebo	middle-aged men with stable incapacitating angina pectoris

death and events prevention